NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Price Target & More

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its earnings results on Tuesday, May, 8th. The biotechnology company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.53 by $0.08. The biotechnology company earned $44 million during the quarter, compared to the consensus estimate of $40.77 million. Enanta Pharmaceuticals had a net margin of 31.60% and a return on equity of 18.50%. The firm's revenue for the quarter was up 388.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.28) EPS. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Enanta Pharmaceuticals.

6 equities research analysts have issued 12 month price targets for Enanta Pharmaceuticals' stock. Their predictions range from $36.00 to $135.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $79.1667 in the next twelve months. View Analyst Ratings for Enanta Pharmaceuticals.

Some companies that are related to Enanta Pharmaceuticals include Valeant Pharmaceuticals Intl (VRX), Alkermes (ALKS), SAGE Therapeutics (SAGE), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), FibroGen (FGEN), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL) and GW Pharmaceuticals (GWPH).

News stories about ENTA stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Enanta Pharmaceuticals earned a news sentiment score of 0.18 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.78 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Enanta Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.34%), Farallon Capital Management LLC (4.75%), Dimensional Fund Advisors LP (3.10%), Franklin Resources Inc. (1.49%), Matarin Capital Management LLC (1.17%) and Prudential Financial Inc. (1.13%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Candriam Luxembourg S.C.A., Franklin Resources Inc., Barclays PLC, Virginia Retirement Systems ET AL, Farallon Capital Management LLC and Northern Trust Corp. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda and Paul J Mellett. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was acquired by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, Prudential Financial Inc., Spark Investment Management LLC, California Public Employees Retirement System, Dimensional Fund Advisors LP, Chicago Equity Partners LLC, UBS Group AG and Russell Investments Group Ltd.. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $115.31.

Enanta Pharmaceuticals has a market capitalization of $2.20 billion and generates $102.81 million in revenue each year. The biotechnology company earns $17.71 million in net income (profit) each year or $0.91 on an earnings per share basis. Enanta Pharmaceuticals employs 89 workers across the globe.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]